E&C Health Subcommittee Holds Hearing on Onshoring America’s Drug Supply Chain

During a June 11 hearing on strengthening the U.S. health care supply chain, members of the House Energy and Commerce (E&C) Health Subcommittee agreed on the need to reduce reliance on foreign sources, but differed in their preferred approaches.

Republicans emphasized national security and praised the Trump Administration’s deregulation and onshoring efforts, while Democrats stressed the importance of federal oversight, adequate funding for public health programs and agencies, and a strong public health infrastructure. Witnesses highlighted key challenges and called for coordinated investments and reforms to build a resilient supply chain. This topic has broad bipartisan, bicameral support, with the hearing building on prior E&C Committee efforts to address supply chain vulnerabilities.

Notably, PBM-related issues were also raised during the hearing including concerns regarding PBM-affiliated biosimilar manufacturing and rebate structures, suggesting these may reinforce the use of higher-cost reference products and stifle biosimilar innovation. Government Affairs continues to work with lawmakers to share our efforts in streamlining access to biosimilars and correct misinformation on biosimilar adoption efforts.